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Abstract
Remarkable progress has been made in some aspects of diabetes care over the last 15 years, but there have
also been a rising number of challenges that differ between high and low-income countries. In high-income
countries, a substantial increase in the use of preventative drugs for cardiovascular disease has lowered
vascular complications and improved diabetes survival. More recently, new classes of diabetes drugs have
emerged that can variably lower cardiovascular outcomes, new-onset heart failure and slow renal decline,
thereby meaningfully increasing the diabetes armoury that should help patients to live even longer lives and
with fewer complications. At the other end of the disease spectrum, we can now better prevent diabetes in
people who are at elevated risk of developing it, whereas other new research has shown that diabetes
remission is possible when lifestyle changes are made in the early years after diagnosis. The downside is that
more people than ever before have type 2 diabetes, so despite such progress in high-income countries, the
absolute burden of disease is rising. Furthermore, it is rising even faster in low and middle-income countries,
where rising adiposity is driving a tidal wave of new diabetes cases; yet, healthcare systems are less able to
cope, lacking sufficient drugs, trained personnel and integrated care systems. Thus, despite advances, the
future challenges from rising diabetes rates worldwide are daunting.
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Background
In the last 15 years we have witnessed some remarkable
changes in the care of patients with type 2 diabetes.
There have been many success stories in high-income
countries, but also – in part arising from successes in
lowering morality rates – a rising prevalence of type 2
diabetes and associated comorbidities [1]. Unfortu-
nately, a simultaneous rise in worldwide adiposity has
fuelled the rising incidence of type 2 diabetes in many
low and middle-income countries, where care systems
are unable to cope with their patients’ needs [2]. Conse-
quently, the ever-increasing numbers of people with the
disease – a trend that seems unlikely to slow or reverse
anytime soon – presents multiple challenges.
The emergence of intensive cardiovascular risk factor
management
Around the early 2000s, the writers of diabetes guidelines
in high-income countries began to recommend the com-
prehensive use of statins and antihypertensives. In the
subsequent few years, this led to considerable improve-
ments in related risk factors, whereas average HbA1c levels
improved more modestly. Improvements in blood pressure
and cholesterol levels allied to population-wide reductions
in smoking rates led, in turn, to considerable improve-
ments in cardiovascular disease (CVD) risk in type 2
diabetes, with evidence of greater reductions in CVD
events in diabetes relative to the background population
[1]. Notably, widespread statin use was recommended on
the mistaken belief that type 2 diabetes represented a
coronary heart disease risk equivalent – something we now
know to be untrue, at least at the time of diagnosis. Never-
theless, many patients with type 2 diabetes were prescribed
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statins at somewhat lower risk thresholds than their
non-diabetic counterparts; a factor contributing to greater
CVD risk reductions in the diabetes population [3]. Despite
our improved knowledge, most countries continue to
recommend statins to all type 2 diabetes patients over the
age of 40 years, with one exception: guidelines for England
and Wales published by the National Institute of Health
and Care Excellence have reverted to risk-scoring such pa-
tients before statins are allocated. A key question to answer
in future will be whether or not cholesterol levels start to
rise in English and Welsh diabetes populations, thus
attenuating CVD gains.
The advent of new diabetes drugs proven to reduce risks
of cardiovascular and related outcomes
Since type 2 diabetes is diagnosed based on glycaemia
levels, important changes over the last 15 years began
with the emergence of multiple new anti-diabetes
therapies (DPP-4 inhibitors, GLP-1-receptor agonists,
and SGLT2 inhibitors). Around the same time, inten-
sive glucose-lowering trials failed to lower mortality or
cardiovascular outcomes, and – in some cases –
caused harm. Added to the rosiglitazone debacle [4],
this led the US Food and Drug Administration and the
European Medicines Agency to recommend all new
diabetes drugs to be tested in cardiovascular outcome
trials [5]. These agencies wanted pharmaceutical com-
panies to demonstrate that their new diabetes drugs
were safe from a cardiovascular perspective. A raft of
cardiovascular outcome trials followed – the remark-
able results of which have now substantially altered
the clinical landscape.
A short summary of the outcome trials reported so
far is useful. Notably, all included patients had existing
cardiovascular disease or were at elevated risk, so the
cardiology community was very attentive to the results.
In the first three trials, all tested DPP-4 inhibitors
proved to be safe from a cardiovascular perspective, al-
though a greater risk of hospitalisation caused by heart
failure was noted for saxagliptin – a finding still unex-
plained [6]. However, there was no evidence of CVD
protection in any of these trials. The fourth trial tested
lixisenatide, a short-acting GLP-1RA, in diabetes pa-
tients after an acute coronary syndrome; it was also
neutral on all counts [7]. At this point, many re-
searchers in the diabetes community began to question
the wisdom of investing so much time, money and ef-
fort in such clinical trials. Some cardiologists ques-
tioned the clinical value of diabetes drugs per se,
arguing that they changed only a surrogate risk marker
(HbA1c), but not hard outcomes. All of these doubts
diminished after investigators leading the EMPAREG
Outcome trial [8] reported their results for empagliflo-
zin in 2013 – results now broadly validated by two
other SGLT2 inhibitor trials (CANVAS [9] and DECLARE
[10]), and by a recent meta-analysis of all three trials [11].
Doubts further lessened with the positive cardiovascular
outcome results of LEADER [12], reported in 2014, which
tested liraglutide. Several other GLP-1RA trials have also
since reported cardiovascular benefits [13], so that now
two broad classes lessen CVD outcomes.
Of particular note are the remarkable and unexpected
beneficial effects of the SGLT2 inhibitors on risks for
heart failure hospitalisation, decline in estimated glom-
erular filtration rate and hard renal outcomes. Further-
more, that these drugs seem to offer such benefits
largely independent of their glycaemic effects has
helped refocus the field on novel risk pathways for
these benefits, as well on providing new understanding
of the complication risks in diabetes [14].
While glycaemia levels are more strongly improved
with the GLP-1RA class of drugs, some novel effect of
these drugs must also, in part, underlie outcome bene-
fits. This is best hinted at by the results of the Harmony
Outcomes trial [15], in which sizeable outcome benefits
occurred despite the modest effects of albiglutide on
established risk factors. There are, of course, important
side effects with both drug classes, such as genital infec-
tions and diabetic ketoacidosis with SGLT2 inhibitors
(necessitating sick day rules advice) and nausea and
vomiting with GLP-1 RAs. That noted, the CVD outcome
benefits of these classes, and their associated weight and
blood pressure reductions and low risk for hypoglycaemia,
mean that multiple clinical guidelines recommend both
drug classes for use in patients with diabetes and existing
CVD. Likewise, the recent consensus published jointly by
the American Diabetes Association and the European As-
sociation for the Study of Diabetes recommends their
wider use [16] and doctors are responding with evidence
of a gradual increase in the use of these medications both
in patients with diabetes and prevalent CVD, and those
at elevated risk of CVD.
SGLT2 inhibitor trials have helped to shine a stronger
spotlight on heart failure risks in type 2 diabetes at a
time when such risks have matched – and even
exceeded – those for acute myocardial infarction or
strokes as first vascular events in diabetes patients. The
diabetes community has thus renewed its interest in the
mechanisms responsible for heart failure, with multiple
new studies targeting the haemodynamic axis, in par-
ticular [17]. Further trials on the SGLT2 class of drugs
in patients with existing heart failure and chronic kidney
disease are ongoing and include patients with both dia-
betes and pre-diabetes [18–22]. If successful, new op-
tions to prevent and treat such conditions will emerge.
Cardiologists and nephrologists are excited by such
prospects and multiple joint meetings have been pro-
moted between relevant specialities.
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Back to the future: getting better at – and more serious
about – lifestyle interventions
Fortunately, progress in type 2 diabetes has not been re-
stricted to greater use of drugs or new drug trial findings,
but extends to an improvement in the delivery of lifestyle
changes. With respect to diabetes prevention, which is
cost-effective, several countries have initiated national
programmes seeking people at elevated risk. How these
develop and whether they make any real dent in the num-
bers of people developing diabetes are major questions of
interest. Many doctors remain sceptical on this point and
believe that only governments and legislative changes di-
rected at the food and drink industry will make any real
inroads to rising obesity levels (and so diabetes rates)
worldwide. I agree.
Beyond prevention, diabetes remission is now an
achievable target for many. The DiRECT trial showed
that using a low-calorie diet to lose around 10 kg of
weight can lead to around half the number of type 2 dia-
betes patients diagnosed within the last six years to no
longer have diabetes one year later. The intervention in-
volved an initial low-calorie (just over 800 kcal per day)
diet phase for 3–5 months, followed by food reintroduc-
tion and a weight maintenance phase. It was
cost-effective and patients’ quality of life improved [23,
24]. The parallel mechanistic insights pointed to striking
improvements in liver fat levels, with weight loss and
evidence of β-cell recovery in the subset undergoing re-
mission, thus tying weight loss to distinct benefits in the
diabetes pathway [25]. These trial results have led the Na-
tional Health Service in England to pilot this intervention
more widely in clinical practice. Several other countries are
also undertaking similar trials in their populations, since
the greatest wish for many diabetes patients is to take fewer
drugs and be free from their type 2 diabetes label [26].
While this approach is exciting, it is clear that more work
is needed to help people maintain their initial weight loss.
Conclusions
There have been multiple changes in the care of people
with type 2 diabetes over the last 15 years, with much to
be optimistic about given the development of better ways
to prevent, reverse or treat diabetes and thus avoid its
major complications. That noted, the biggest challenge re-
mains the increasing number of people worldwide who are
overweight or obese, leading to an inevitable rise in type 2
diabetes rates in nearly all countries. Yet, I and many
others believe that the obesity epidemic cannot be solved
by the medical profession but only by governments.
However, few, if any, national governments appear to take
these issues seriously. The increasing number of younger
people with type 2 diabetes is a particular cause for con-
cern because the condition worsens more rapidly in youn-
ger people, leading to greater life years lost. In high-income
countries, the other challenge that paradoxically arises
from our improved ability to prevent premature deaths
from CVD, cancer and other chronic conditions, is that
more people with such conditions are living longer and
thus able to develop type 2 diabetes. At the same time, im-
proved survival in diabetes per se gives these patients more
time to develop other chronic conditions. The conse-
quence is a rise in the number of people with comorbidity
– an issue set to add to the complexities of diabetes care in
the future. Finally, the rapid rise in diabetes rates in many
low and middle-income countries challenges many health
systems worldwide. Sadly, a lack of resources, including
drugs, plus too few trained healthcare professionals and a
lack of integrated care systems, means that diabetes is set
to become a far more common cause of morbidity and
mortality in many countries.
Abbreviation
CVD: Cardiovascular disease
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